BioCardia wins Nasdaq extension to Oct. 7 to meet $2.5 million equity rule

BioCardia, Inc.

BioCardia, Inc.

BCDA

0.00
  • BioCardia received a Nasdaq notice that stockholders’ equity fell below the USD 2.5 million minimum under Listing Rule 5550(b)(1).
  • Nasdaq granted an extension to Oct. 7, 2026 to regain compliance following submission of a plan on May 25, 2026.
  • BioCardia raised USD 4.9 million net via an at-the-market sale of 4,004,330 shares at an average USD 1.27 from April 1 to June 5, 2026.
  • BioCardia believes stockholders’ equity now exceeds USD 2.5 million; Nasdaq will monitor compliance at the next periodic report.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-020384), on June 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.